RNA m5C methylation orchestrates BLCA progression via macrophage reprogramming
Journal of Cellular and Molecular Medicine · 2023-08 · 27 (16) · 2398-2411
DOI: 10.1111/jcmm.17826 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 05.07.2023. Verfasst von Dali Yan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Affiliated Huai'an Hospital of Xuzhou Medical University and the Second People's Hospital of Huai'an, Huai'an, China. Hauptthemen laut MEDLINE: Epigenesis, Genetic, RNA. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Recently, epigenetics showed essential roles in tumour microenvironment (TME) and immunotherapy response, however, the functions of RNA 5‐methylcytosine (m5C) modification in TME remains unknown. According to 13 m5C regulators, we evaluated 412 BLCA patients from The Cancer Genome Atlas (TCGA) database. The m5C score was constructed by unsupervised clustering analysis and principal component analysis (PCA) algorithms. Gene set variation analysis (GSVA), ESTIMATE algorithm, and immunohistochemical (IHC) staining were performed. Macrophage chemotaxis assay was used to assess the M2 macrophages. Among the 412 patients, the frequency of mutation was 13%. m5C regulators was expressed significantly in BLCA tissue compared with normal tissue. Then, two m5C methylation modification patterns were identified with dissimilar TME cell infiltration patterns. The C1 alteration pattern in the m5C cluster was connected with better survival. In addition, we found that NSUN6 was highly correlated with recruitment of macrophages via bioinformatics and IHC. Further experiment validated that NSUN6 promoted HDAC10 expression by mediating m5C methylation, inhibited the transcription of macrophage‐associated chemokines and thus inhibited the recruitment of M2 macrophages. The m5C score constructed by m5C modification pattern showed that high m5C score group had a better prognosis. This study uncovered the significant roles of m5C modifications in modulating the TME and indicated that NSUN6 could inhibit the recruitment of M2 macrophages via m5C methylation, which provided novel insight into epigenetic regulation of TME and clinical suggestions for immunotherapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Affiliated Huai'an Hospital of Xuzhou Medical University and the Second People's Hospital of Huai'an, Huai'an, China.
- Department of Geriatrics, The Third Hospital of Kunshan City, Kunshan, China.
- Department of Urology, The Affiliated Huai'an Hospital of Xuzhou Medical University and the Second People's Hospital of Huai'an, Huai'an, China.
- Department of Pathology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China.
- Department of Oncology, Lian Shui People's Hospital Affiliated to Kangda College of Nanjing Medical University, Huai'an, China.
ORCID-Profile: Hao Luo
Zitieren
APA
Yan, D., Xie, Y., Huang, L., Zhang, Y., Gu, R., Xie, H., Huang, X., & Luo, H. (2023). RNA m5C methylation orchestrates BLCA progression via macrophage reprogramming. Journal of Cellular and Molecular Medicine, 27(16), 2398-2411. https://doi.org/10.1111/jcmm.17826
Vancouver
Yan D, Xie Y, Huang L, Zhang Y, Gu R, Xie H, et al. RNA m5C methylation orchestrates BLCA progression via macrophage reprogramming. Journal of Cellular and Molecular Medicine. 2023;27(16):2398-2411. doi:10.1111/jcmm.17826
BibTeX
@article{Yan2023,
author = {Yan, Dali and Xie, Yongsong and Huang, Liyuan and Zhang, Yi and Gu, Runhuan and Xie, Huaibing and Huang, Xing and Luo, Hao},
title = {RNA m5C methylation orchestrates BLCA progression via macrophage reprogramming},
journal = {Journal of Cellular and Molecular Medicine},
year = {2023},
volume = {27},
number = {16},
pages = {2398--2411},
doi = {10.1111/jcmm.17826}
}
EUVIMED